January 12, 2018 10:02 AM ESTUpdated 01:26 PM
Pharma

In a pi­o­neer­ing first, As­traZeneca scores FDA OK to use its PARP against breast can­cer

John Carroll

Editor & Founder

As­traZeneca $AZN has picked up an­oth­er key win for its can­cer drug fran­chise.

The FDA ap­proved its PARP in­hibitor Lyn­parza for BR­CA-mu­tat­ed metasta­t­ic breast …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times